Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer

from The Lancet in conversation with · host The Lancet Group

Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Oct 17, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer

0:00 22:09

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet in conversation with?

This episode is 22 minutes long.

When was this The Lancet in conversation with episode published?

This episode was published on October 17, 2025.

Can I download this The Lancet in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!